Form 4: Karyopharm Therapeutics CEO Richard Paulson Sells Shares to Cover Tax Obligations

Richard Paulson, CEO of Karyopharm Therapeutics, sold 3,608 shares of common stock on August 6, 2024, to cover withholding tax liabilities.

Summary

• Richard Paulson, the CEO of Karyopharm Therapeutics Inc., sold 3,608 shares of common stock on August 6, 2024.
• The sale was executed at a price of $0.9299 per share.
• The transaction was conducted under a pre-arranged automatic sale plan adopted on June 10, 2021.
• The purpose of the sale was to cover withholding tax liabilities incurred upon the vesting of restricted stock units.
• Following the transaction, Paulson directly owns 1,142,881 shares of Karyopharm Therapeutics Inc.

Sentiment

Score: 6

Explanation: The sentiment is neutral as the transaction is related to tax obligations and was pre-planned. It doesn't necessarily reflect a positive or negative outlook on the company's performance.

Positives

• The sale was conducted under a pre-arranged plan, indicating it was not a discretionary trade based on current market conditions.

Industry Context

Form 4 filings are a routine part of regulatory compliance for corporate insiders and are closely watched by investors for insights into management's perspective on the company's stock.

Stakeholder Impact

• The sale of shares by the CEO could have a minor impact on shareholder sentiment, although it is unlikely to be significant given the reason for the sale.

Key Dates